Tablas de Dosis Calculadora Mezclas & Stacks Aprender Blog Péptidos
Abrir Calculadora
Tablas de Dosis  ›  Dulaglutide
GLP-1 / Metabolic

Dulaglutide Guía & Tabla de Dosis

A once-weekly GLP-1 agonist researched for metabolic outcomes.

También conocido comoTrulicity
Víasubcutaneous
Dulaglutide — Tabla de dosis
Cada fila citada
ObjetivoDosisFrecuenciaDuraciónEvidenciaFuente
Glycemic control in type 2 diabetes (low dose) 0.75 mg 1x/week 40 weeks Clinical PMID 29397376
Glycemic control in type 2 diabetes (high dose) 1.5 mg 1x/week 40 weeks Clinical PMID 29397376
Cardiovascular risk reduction in type 2 diabetes with atherosclerotic cardiovascular disease 1.5 mg 1x/week per trial Clinical PMID 41406444
Solo para uso de investigación y educativo. No es consejo médico.

What is Dulaglutide?

Dulaglutide — sold under the brand name Trulicity — is a once-weekly injectable peptide that belongs to a class called GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1, a natural hormone your gut releases after you eat. Dulaglutide mimics that hormone in a longer-lasting form, so a single weekly injection keeps it active in the body all week. It has been widely studied in people with type 2 diabetes and is frequently used as an active comparator in clinical trials testing newer metabolic compounds.[1]

How Dulaglutide Works

Think of GLP-1 as a helpful messenger your gut sends to your pancreas after a meal. It says, "Hey, blood sugar just went up — release some insulin, and hold back glucagon (the hormone that raises sugar)." The problem is that natural GLP-1 breaks down in minutes. Dulaglutide is an engineered version of that messenger, redesigned so the body can't break it down quickly. It attaches to the same GLP-1 receptors and delivers the same signal — but for days instead of minutes.[1]

Beyond blood sugar, GLP-1 receptor activation also slows down how fast food leaves the stomach and signals the brain to reduce appetite. That's why GLP-1 agonists like dulaglutide are associated with weight loss in research settings.[1]

What the Research Shows

Dulaglutide has appeared in multiple head-to-head clinical trials, often as the benchmark that newer compounds are measured against.

Versus Semaglutide (SUSTAIN 7 Trial)

In one large phase 3b trial — the SUSTAIN 7 study — researchers compared dulaglutide directly with semaglutide (another once-weekly GLP-1 agonist) in over 1,200 people with type 2 diabetes on metformin. At the lower dose pairing, semaglutide reduced HbA1c (a measure of average blood sugar over ~3 months) by 1.5 percentage points, compared to 1.1 points with dulaglutide 0.75 mg. At the higher dose pairing, semaglutide cut HbA1c by 1.8 points versus 1.4 points for dulaglutide 1.5 mg. Body weight also dropped more with semaglutide — about 4.6 kg versus 2.3 kg at low doses, and 6.5 kg versus 3.0 kg at high doses. Both drugs had similar safety profiles, with gastrointestinal side effects (nausea, vomiting, diarrhea) being the most common complaint in both groups.[1]

Versus Tirzepatide (SURPASS J-mono Trial)

In a Japanese phase 3 trial, the dual GIP/GLP-1 agonist tirzepatide was compared to dulaglutide 0.75 mg in 636 patients over 52 weeks. All three tirzepatide doses (5, 10, and 15 mg) produced significantly greater HbA1c reductions than dulaglutide — ranging from 1.1 to 1.5 percentage points more. Weight loss was also substantially larger with tirzepatide. Dulaglutide participants lost about 0.5 kg on average, while tirzepatide participants lost between 5.8 and 10.7 kg depending on dose.[3]

Versus Oral Orforglipron (Phase 2 Trial)

In a phase 2 study testing the oral (pill-form) GLP-1 agonist orforglipron, dulaglutide 1.5 mg served as the active comparator. Dulaglutide reduced HbA1c by about 1.1% and body weight by roughly 3.9 kg over 26 weeks. Orforglipron at higher doses outperformed dulaglutide on both measures.[2]

Meta-Analysis Perspective

A 2025 systematic review and meta-analysis comparing several GLP-1 agents found that semaglutide generally showed greater efficacy than dulaglutide for both glycemic control and weight reduction, while dulaglutide remains a well-characterized, widely studied reference compound in its class.[4]

Switching and Escalation Research

Research has also looked at what happens when patients already on dulaglutide switch to other agents or move to higher doses. One randomized trial found that switching from lower-dose dulaglutide to tirzepatide produced better glycemic outcomes than simply escalating the dulaglutide dose.[6] Another study found improvements when patients switched from dulaglutide to subcutaneous semaglutide.[5]

What Dulaglutide Is Being Studied For

  • Glycemic control in type 2 diabetes — reducing HbA1c and fasting blood glucose[1]
  • Body weight reduction — as a secondary outcome in most metabolic trials[1]
  • Cardiovascular risk — studied in patients with type 2 diabetes and established atherosclerotic cardiovascular disease
  • Active comparator role — used as a benchmark in trials for tirzepatide, semaglutide, and novel oral GLP-1 agents[2][3]

How Dulaglutide Is Dosed in Research

Research protocols have used two main dose levels administered once weekly by subcutaneous injection — the lower level studied over 40 weeks for glycemic control, and the higher level used both for glycemic endpoints and cardiovascular outcome research. The exact figures, durations, and study contexts are laid out in the dosage chart on this page. If you want to explore dose calculations further, the calculator on this site can help you work through the numbers. All dosing information here is for research reference only and does not constitute medical advice.

Mixing and Storing Dulaglutide

Dulaglutide as studied in clinical trials comes as a ready-to-use solution in a prefilled pen or syringe — it does not require reconstitution (mixing with water or a solvent) before use. In research settings, the pre-filled solution is typically stored in a refrigerator at 2–8°C (36–46°F) and should never be frozen. If kept at room temperature (up to 30°C / 86°F), it remains stable for a limited period — check the specific lot documentation. The solution should be clear and colorless to slightly yellow before use; any particles or discoloration are a sign it should not be used. As with all research peptides, proper cold-chain handling and documentation are essential for maintaining integrity in a study setting.

Sources

  1. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. — The lancet. Diabetes & endocrinology, 2018. PMID 29397376.
  2. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. — Lancet (London, England), 2023. PMID 37369232.
  3. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. — The lancet. Diabetes & endocrinology, 2022. PMID 35914543.
  4. Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis. — Frontiers in pharmacology, 2025. PMID 40444045.
  5. Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study). — Diabetes, obesity & metabolism, 2023. PMID 36722623.
  6. Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial. — Annals of internal medicine, 2025. PMID 40183678.

Dulaglutide Preguntas

What is Dulaglutide?
Dulaglutide is a once-weekly injectable GLP-1 receptor agonist — a compound that mimics the natural gut hormone GLP-1. It has been studied extensively in clinical trials for type 2 diabetes and is often used as a comparison drug when researchers test newer metabolic agents like tirzepatide or oral GLP-1 pills.[1] It is a research compound; this information is not medical advice.
How does Dulaglutide work?
Dulaglutide binds to GLP-1 receptors — the same targets as the natural hormone your gut releases after meals. This stimulates insulin release, suppresses glucagon (a blood-sugar-raising hormone), slows stomach emptying, and reduces appetite signals in the brain. Its engineered structure makes it resistant to rapid breakdown, so one dose stays active for roughly a week.[1]
What is Dulaglutide used for in research?
Research has focused on glycemic control in type 2 diabetes, body weight outcomes, and cardiovascular risk reduction. Dulaglutide also serves as an active comparator in trials of newer agents — including tirzepatide[3] and the oral GLP-1 agonist orforglipron[2] — making it a key benchmark for understanding how next-generation compounds perform relative to an established standard.
How is Dulaglutide dosed in research studies?
Clinical trials have used 0.75 mg and 1.5 mg once-weekly subcutaneous injections. Both doses have been tested over 40-week periods for glycemic control, and 1.5 mg has been studied in cardiovascular outcome trials.[1] See the dosage chart on this page for the full breakdown and use the calculator for dose calculations. This is research reference information only.
How do you reconstitute Dulaglutide?
Dulaglutide used in clinical research comes as a pre-filled, ready-to-inject solution — no reconstitution (mixing with a solvent) is needed. It should be stored refrigerated at 2–8°C, never frozen, and inspected for particles or unusual color before use. Proper cold-chain storage is important for maintaining the compound's integrity in a research setting.
Is Dulaglutide safe based on research data?
In clinical trials, the most commonly reported side effects were gastrointestinal — nausea, vomiting, and diarrhea — consistent with the broader GLP-1 class. In SUSTAIN 7, about 33–48% of participants reported GI events depending on the dose.[1] Severe hypoglycemia was rare.[2] All safety data refer to controlled research settings; this is not medical advice about individual risk.